Drug Trial Radar · NCT00685477
Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying
Last checked: Nov 19, 2026Latest source record: Feb 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
May 2008
Primary completion
May 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- Temple UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Johns Hopkins University; Penn State University; Memorial Health University Medical Center
- First posted
- May 28, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
Conditions
- Healthy
Interventions
Experimental Sequence ABCDrug
Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes
Experimental Sequence ACBDrug
Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes
Experimental Sequence BACDrug
Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion
Experimental Sequence BCADrug
Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion
Experimental Sequence CABDrug
Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion
Experimental Sequence CBADrug
Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Coefficient of Variation (CV) for Gallbladder Ejection Fraction (GBEF) for Each Infusion MethodTime frame: 15, 30, 45, and 60 minutes post drug infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Temple University Hospital
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.